https://scholars.lib.ntu.edu.tw/handle/123456789/638188
標題: | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study | 作者: | Pant, Shubham Schuler, Martin Iyer, Gopa Witt, Olaf Doi, Toshihiko Qin, Shukui Tabernero, Josep Reardon, David A Massard, Christophe Minchom, Anna Lugowska, Iwona Carranza, Omar Arnold, Dirk Gutierrez, Martin Winter, Helen Stuyckens, Kim Crow, Lauren Najmi, Saltanat Hammond, Constance Thomas, Shibu Santiago-Walker, Ademi Triantos, Spyros Sweiti, Hussein Loriot, Yohann CHIH-HUNG HSU |
公開日期: | 八月-2023 | 卷: | 24 | 期: | 8 | 來源出版物: | The Lancet. Oncology | 摘要: | FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638188 | ISSN: | 14702045 | DOI: | 10.1016/S1470-2045(23)00275-9 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。